WebNov 8, 2024 · GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study that showed the investigational candidate improved or maintained hemoglobin levels without an increase in cardiovascular risk. GSK’s clinical success positions the company to take the ... WebJan 24, 2024 · Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) ... GlaxoSmithKline: ClinicalTrials.gov Identifier: NCT03029208 Other Study ID Numbers: 201410 2016-000507-86 ( EudraCT Number )
GlaxoSmithKline Company Information - Drugs.com
WebThe homepage of the GSK USA website. Press releases. 27 March 2024 Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone ; 14 March 2024 GSK and Earvin “Magic” Johnson Partner to Raise … WebFeb 1, 2024 · About anemia of chronic kidney disease CKD, characterised by progressive loss of kidney function, is an increasing global public health burden. [iii] Risk factors for CKD include hypertension, diabetes, obesity and primary renal disorders. iii Furthermore, CKD is an independent risk factor for cardiovascular disease. iii Anemia is an important ... ice cream and ices
Specialty GSK US
WebJul 21, 2024 · The drug is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for patients with anemia due to chronic kidney disease (CKD). CKD, characterized by progressive loss of kidney function, is a growing global health concern. WebJun 29, 2024 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anaemia due to chronic kidney disease … WebOct 18, 2024 · GlaxoSmithKline (GSK) plc will present eight abstracts at the upcoming American Society of Nephrology Kidney Week 2024, being held virtually from 4-7 November 2024, including new data that advance science and has the potential to deliver significant medical innovation for patients with kidney disease. ice cream aston pa